特鋭德(300001.SZ)預中標中國華能新能源升壓站項目
格隆匯5月25日丨特鋭德(300001.SZ)公佈,近日,中國華能集團有限公司(以下簡稱“中國華能”)近期在其電子商務平台公示了中國華能集團有限公司2021年度新能源升壓站設備框架協議採購的中標情況,公司為其部分項目中標候選人。
特鋭德本次成功中標的是中國華能集團有限公司2021年度新能源升壓站設備框架協議預製艙採購及安裝調試(北區)標段,本標段中標的預估容量為2200MVA,佔中國華能本次預製艙模塊化變電站集中採購總招標量的55%,預計中標金額約2.1295億元。該項目金額(除税後)約佔公司最近一期經審計年度銷售收入的2.54%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.